Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098163 | 0.84 | GSK3B (0.40) | PTGS1PTGS2SMN1; SMN2MAPTMET | |
| SCHEMBL5098222 | 0.84 | DYRK1A (0.41) | PTGS1PTGS2RAB9ASMN1; SMN2DYRK1A | |
| SCHEMBL5094797 | 0.84 | RAB9A (0.39) | RAB9ASMN1; SMN2DYRK1AMAPTNPC1 | |
| SCHEMBL5101554 | 0.83 | NPC1 (0.38) | PTGS1PTGS2RAB9AMAPTCHRM5 | |
| SCHEMBL5107984 | 0.83 | RAB9A (0.37) | RAB9ASMN1; SMN2DYRK1AMAPTCHRM5 | |
| SCHEMBL5108059 | 0.82 | NPBWR1 (0.44) | PTGS1PTGS2MAPTCYP2D6NPBWR1 | |
| SCHEMBL1925023 | 0.81 | PTGS2 (0.34) | PTGS1PTGS2CRHR1 | |
| SCHEMBL5102133 | 0.81 | CYP11B2 (0.37) | RAB9ASMN1; SMN2DYRK1AMAPTCHRM5 | |
| SCHEMBL1925362 | 0.81 | PTGS2 (0.46) | PTGS1PTGS2 | |
| SCHEMBL5108630 | 0.81 | GSK3B (0.40) | PTGS1PTGS2MAPTNPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314877-B2 | Benzofuran derivative | KOWA CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-20060189621-A1 | Benzofuran derivative | KOWA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1602655-A1 | BENZOFURAN DERIVATIVE | Kowa Co., Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189621-A1 | Benzofuran derivative | TNF, TNFRSF1A, RELA | PTGS1 28/4885PTGS2 114/4885RAB9A 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.